{"entity":{"id":"nct06890065","kind":"trial","name":"JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia","aka":[],"tldr":"An early trial of JY231 run by Shenzhen Genocury Biotech Co., Ltd., now recruiting.","summary":"JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia is an interventional study registered as NCT06890065 by Shenzhen Genocury Biotech Co., Ltd., with 20 participants planned, started 2025-03-01, primary completion expected 2027-12. Conditions recorded: B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma. Interventions recorded: JY231 Injection. The registry gives the phase as not applicable.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06890065","url":"https://clinicaltrials.gov/study/NCT06890065"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["jy231"],"companies":["genocury-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06890065","phase":"not-applicable","setting":"An Early-Phase Exploratory Clinical Study of JY231 Injection in Relapsed/Refractory B-Cell Lymphoma/Leukemia: Safety, Tolerability, and Preliminary Efficacy","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06890065/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"jy231","kind":"drug","name":"JY231","route":"/drugs/jy231/"}],"company":[{"id":"genocury-biotech","kind":"company","name":"Genocury Biotech","route":"/companies/genocury-biotech/"}]}}